SNY is good value based on its earnings relative to its share price (8.48x), compared to the US market average 18.56x)
Valuation
SNY is good value based on its earnings relative to its share price (8.48x), compared to the US Drug Manufacturers - General industry average (8.49x)
Valuation
SNY is good value based on its book value relative to its share price (1.66x), compared to the US market average (-0.01x)
Valuation
1 of 12
SNY News
Valuation
SNY fair value
Fair Value of SNY stock based on Discounted Cash Flow (DCF)
Price
$50.77
Fair Value
$55.93
Undervalued by
9.23%
SNY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
8.48x
Industry
8.49x
Market
18.56x
SNY is good value based on its earnings relative to its share price (8.48x), compared to the US market average 18.56x)
Valuation
SNY is good value based on its earnings relative to its share price (8.48x), compared to the US Drug Manufacturers - General industry average (8.49x)
Valuation
SNY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.66x
Industry
5.16x
Market
-0.01x
SNY is good value based on its book value relative to its share price (1.66x), compared to the US market average (-0.01x)
Valuation
SNY is good value based on its book value relative to its share price (1.66x), compared to the US Drug Manufacturers - General industry average (5.16x)
Valuation
SNY's financial health
Profit margin
Revenue
$45.6B
Net Income
$15.0B
Profit Margin
33%
SNY's Earnings (EBIT) of $17.70B can safely cover interest payments on company debt ($28.87B)
Financials
SNY's profit margin has increased (+25.5%) in the last year from (7.5%) to (33%)
Financials
Assets to liabilities
Assets
$139.7B
Liabilities
$62.7B
Debt to equity
0.38
SNY's short-term assets ($41.10B) exceed its short-term liabilities ($23.47B)
Financials
SNY's short-term assets ($41.10B) exceed its long-term liabilities ($39.19B)
Financials
SNY's debt has increased relative to shareholder equity (0.82), over the past 5 years ago (0.76)
Financials
SNY's debt to equity ratio (0.82) is considered high
Financials
Cash flow
Operating
$9.1B
Investing
$4.4B
Financing
-$7.9B
SNY's operating cash flow ($9.08B) is sufficient to service the company's debt ($28.87B)
Financials
Sanofi Stock FAQ
What is Sanofi's quote symbol?
(NASDAQ: SNY) Sanofi trades on the NASDAQ under the ticker symbol SNY. Sanofi stock quotes can also be displayed as NASDAQ: SNY.
What is the 52 week high and low for Sanofi (NASDAQ: SNY)?
(NASDAQ: SNY) Sanofi's 52-week high was $55.00, and its 52-week low was $43.17. It is currently -7.69% from its 52-week high and 17.6% from its 52-week low.
How much is Sanofi stock worth today?
(NASDAQ: SNY) Sanofi currently has 1,253,826,630 outstanding shares. With Sanofi stock trading at $50.77 per share, the total value of Sanofi stock (market capitalization) is $127.31B.
Sanofi stock was originally listed at a price of $29.77 in Jul 1, 2002. If you had invested in Sanofi stock at $29.77, your return over the last 18 years would have been 70.54%, for an annualized return of 3.01%.
How much is Sanofi's stock price per share?
(NASDAQ: SNY) Sanofi stock price per share is $50.77 today (as of Apr 9, 2021).
What is Sanofi's Market Cap?
(NASDAQ: SNY) Sanofi's market cap is $127.31B, as of Apr 12, 2021.
Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
Sanofi's market cap is calculated by multiplying SNY's current stock price of $50.77 by SNY's total outstanding shares of 1,253,826,630.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.